Bob has a special mission as CEO of the Cleveland-based startup Diasome. He lives with type 1 diabetes himself, and passionately believes that his company can make injected insulin work better in the bodies of people with diabetes. He has 25 years' experience in diabetes drug development, including involvement and leadership in the execution of more than 20 human clinical studies on improved insulin therapies. As the co-founder and CEO of Diasome, he's responsible for aligning technology, clinical, and business teams in Diasome’s work to achieve the first approved liver-targeted insulin therapyGet their bookView their FacebookView their InstagramView their LinkedInView their Twitter
To my friends, colleagues, and community members, first and foremost, I hope you and your families are remaining healthy and safe during these challenging times. I would like to take this opportunity to update you on the recent progress Diasome Pharmaceuticals has made and what we are looking to accomplish moving forward.
In June, we attended The American Diabetes Association's 80th Scientific Sessions virtually where we presented topline data from our Phase 2b OPTI-1 study of hepatocyte directed vesicle technology in type 1 diabetes. Having been diagnosed with type 1 diabetes more than 25 years ago, I understand the hesitation rapid-acting insulin users face because of associated increased risk of hypoglycemia. With the OPTI-1 study, we saw reductions in Level 2 hypoglycemic events (defined as at least 15 consecutive minutes of CGM measured blood glucose less than 54 mg/dL) during the 90-day treatment period when patients received HDV added to lispro, validating that HDV technology when added to mealtime insulin has the potential to decrease time spent in hypoglycemia. These results are consistent with the Level 2 hypoglycemia reductions in the Phase 2b ISLE-1 study that we reported in Diabetes Care in November 2019.
Taken together, data from ISLE-1 and OPTI-1 strongly support the conclusion that our technology restores the glucose storage and release function of the liver in order to prevent both hyper- and hypoglycemia. These two trials represent a significant technical achievement in modern insulin development, showing that insulin directed to the liver at mealtime actually prevents hypoglycemia.
Of course, this was only one of many exciting discussions at the meeting. I would be remiss not to give a nod to my fellow researchers and innovators in the space who share our team’s passion for developing improved therapies, additional research, and most importantly, better outcomes for people with diabetes. The reality of the sub-optimal nature of insulin therapy still remains; and that is what motivates us to continue to make progress.
After having completed more than 20 Phase 2 and Phase 2b clinical trials in people with type 1 and type 2 diabetes, we look forward to beginning Phase 3 trials in 2021 to evaluate HDV as an additive to insulin that physiologically prevents hypoglycemia. Each day we move our technology one step further towards availability for those that could benefit from it.
We also look forward to continuing to be an ally to our community. As we all know, type 1 and type 2 diabetes affect people from all backgrounds, in every geography. Diasome is committed to doing its part to provide new, safe, effective, and affordable solutions to alleviate suffering in the diabetes community.
For more information about our growth and future goals, be sure to follow Diasome on Twitter (@Diasome) and LinkedIn (@Diasome Pharmaceuticals). For additional details visit: www.diasome.com
Robert Geho, co-founder and chief executive officer
Share your story with us.
Diasome seeks to serve people with diabetes by developing cutting-edge therapies and by serving as a forum for our community to educate and inform others about the challenges and successes in living with diabetes. We actively seek perspectives from the rich and diverse world of clinicians, scientists, thought leaders and people with diabetes. To share your unique perspective with us, email Diasome at firstname.lastname@example.org